Ultrasound and Cisplatin Combined Treatment of Human Melanoma
Cells A375—the Study of Sonodynamic Therapy

J 2012

Ultrasound and Cisplatin Combined Treatment of Human Melanoma Cells A375—the Study of Sonodynamic Therapy

BERNARD, Vladan; Vojtěch MORNSTEIN; Jiřina ŠKORPÍKOVÁ a Josef JAROŠ

Základní údaje

Originální název

Ultrasound and Cisplatin Combined Treatment of Human Melanoma Cells A375—the Study of Sonodynamic Therapy

Název česky

Kombinované působení ultrazvuku a cisplatiny na nádorové lidské buňky A375 - studie sonodynamického efektu

Autoři

BERNARD, Vladan ; Vojtěch MORNSTEIN ; Jiřina ŠKORPÍKOVÁ a Josef JAROŠ

Vydání

Ultrasound in Medicine and Biology, 2012, 0301-5629

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10610 Biophysics

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.455

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/12:00060116

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1016/j.ultrasmedbio.2012.02.006

UT WoS

000304995600014

Klíčová slova anglicky

A375; cisplatin; ultrasound; viability

Změněno: 22. 4. 2013 14:17, Soňa Böhmová

Anotace

V originále

Sonodynamic therapy, an effect of low-power ultrasound field and the anticancer drug cisplatin was studied in vitro on human melanoma cells A375. The viability of cells has been studied by standard MTT test according to different modes of treatment: application of cisplatin alone, exposure of ultrasound field alone, exposure to ultrasound followed by cisplatin, and application of cisplatin followed by exposure to ultrasound. Ultrasound was used at a therapeutical intensity of 1 Wcm-2 for 10 min. Concentration of cisplatin in the cell suspension was always 2,3 mikroM. The results show that sonodynamic therapy is one of the possibilities how to intensify standard cytostatic therapy. This conclusion is supported by reducing the viability of studied cells, especially 72 hours after the treatment. The time sequence of application of ultrasonic field and cytostatics appears to be a significant factor affecting the changes in cell’s viability. Maximum suppression of viability has been found when applying the experimental design involving application of cisplatin followed by exposure to ultrasound; the final value of viability of combined affected cells was more than ten percent lower than for alone cisplatin treatment.

Citovat

BERNARD, Vladan; Vojtěch MORNSTEIN; Jiřina ŠKORPÍKOVÁ a Josef JAROŠ. Ultrasound and Cisplatin Combined Treatment of Human Melanoma Cells A375—the Study of Sonodynamic Therapy. Ultrasound in Medicine and Biology. 2012, roč. 38, č. 7, s. 1205-1211. ISSN 0301-5629. Dostupné z: https://doi.org/10.1016/j.ultrasmedbio.2012.02.006.

@article{984198,
   author = {Bernard, Vladan and Mornstein, Vojtěch and Škorpíková, Jiřina and Jaroš, Josef},
   article_number = {7},
   doi = {https://doi.org/10.1016/j.ultrasmedbio.2012.02.006},
   keywords = {A375; cisplatin; ultrasound; viability},
   language = {eng},
   issn = {0301-5629},
   journal = {Ultrasound in Medicine and Biology},
   title = {Ultrasound and Cisplatin Combined Treatment of Human Melanoma Cells A375—the Study of Sonodynamic Therapy},
   volume = {38},
   year = {2012}
}

TY  - JOUR
ID  - 984198
AU  - Bernard, Vladan - Mornstein, Vojtěch - Škorpíková, Jiřina - Jaroš, Josef
PY  - 2012
TI  - Ultrasound and Cisplatin Combined Treatment of Human Melanoma Cells A375—the Study of Sonodynamic Therapy
JF  - Ultrasound in Medicine and Biology
VL  - 38
IS  - 7
SP  - 1205-1211
EP  - 1205-1211
SN  - 03015629
KW  - A375
KW  - cisplatin
KW  - ultrasound
KW  - viability
N2  - Sonodynamic therapy, an effect of low-power ultrasound field and the anticancer drug cisplatin was studied in vitro on human melanoma cells A375. The viability of cells has been studied by standard MTT test according to different modes of treatment: application of cisplatin alone, exposure of ultrasound field alone, exposure to ultrasound followed by cisplatin, and application of cisplatin followed by exposure to ultrasound. Ultrasound was used at a therapeutical intensity of 1 Wcm-2 for 10 min. Concentration of cisplatin in the cell suspension was always 2,3 mikroM. The results show that sonodynamic therapy is one of the possibilities how to intensify standard cytostatic therapy. This conclusion is supported by reducing the viability of studied cells, especially 72 hours after the treatment. The time sequence of application of ultrasonic field and cytostatics appears to be a significant factor affecting the changes in cell’s viability. Maximum suppression of viability has been found when applying the experimental design involving application of cisplatin followed by exposure to ultrasound; the final value of viability of combined affected cells was more than ten percent lower than for alone cisplatin treatment.
ER  -

BERNARD, Vladan; Vojtěch MORNSTEIN; Jiřina ŠKORPÍKOVÁ a Josef JAROŠ. Ultrasound and Cisplatin Combined Treatment of Human Melanoma Cells A375—the Study of Sonodynamic Therapy. \textit{Ultrasound in Medicine and Biology}. 2012, roč.~38, č.~7, s.~1205-1211. ISSN~0301-5629. Dostupné z: https://doi.org/10.1016/j.ultrasmedbio.2012.02.006.

Přehled o publikaci